Cargando…
The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling
Glioma is the most prevalent brain tumor, presenting with limited treatment options, while patients with malignant glioma and glioblastoma (GBM) have poor prognoses. The physical obstacle to drug delivery imposed by the blood‒brain barrier (BBB) and glioma stem cells (GSCs), which are widely recogni...
Autores principales: | Qu, Jiaorong, Qiu, Bojun, Zhang, Yuxin, Hu, Yan, Wang, Zhixing, Guan, Zhiang, Qin, Yiming, Sui, Tongtong, Wu, Fan, Li, Boyang, Han, Wei, Peng, Xiaozhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630452/ https://www.ncbi.nlm.nih.gov/pubmed/37935665 http://dx.doi.org/10.1038/s41392-023-01666-3 |
Ejemplares similares
-
Gambogic amide inhibits angiogenesis by suppressing VEGF/VEGFR2 in endothelial cells in a TrkA-independent manner
por: Sui, Tongtong, et al.
Publicado: (2021) -
A Gamboge Case
por: Biegler, J. A.
Publicado: (1887) -
Effects of the selective TrkA agonist gambogic amide on pigmentation and growth of human hair follicles in vitro
por: Campiche, Remo, et al.
Publicado: (2019) -
The selective TrkA agonist, gambogic amide, promotes osteoblastic differentiation and improves fracture healing in mice
por: Johnstone, Maddison R., et al.
Publicado: (2019) -
Research Progress in the Field of Gambogic Acid and Its Derivatives as Antineoplastic Drugs
por: Li, Meng, et al.
Publicado: (2022)